Transcatheter Pulmonary Valve Implantation
Summary
Transcatheter pulmonary valve implantation with an FDA-approved valve is considered medically necessary for individuals with congenital heart disease and current right ventricular outflow tract (RVOT) obstruction or regurgitation, including right ventricle-to-pulmonary artery conduit or native or patched RVOT with at least moderate pulmonic regurgitation, or pulmonic stenosis with a mean RVOT gradient of at least 35 mm Hg. It is considered investigational for all other indications. The 10/19/2026 policy history entry records a description update regarding devices, with the policy statements unchanged, and a code reference update that removed ICD-9 procedure and diagnosis codes.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.